Takeda Pharmaceutical Company Limited (NYSE:TAK) Stake Cut by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,265 shares of the company’s stock after selling 1,799 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $316,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Bridgefront Capital LLC bought a new stake in Takeda Pharmaceutical in the second quarter valued at $200,000. Cutter & CO Brokerage Inc. bought a new stake in Takeda Pharmaceutical in the third quarter valued at $464,000. Macquarie Group Ltd. lifted its stake in Takeda Pharmaceutical by 10.2% in the second quarter. Macquarie Group Ltd. now owns 4,740,712 shares of the company’s stock valued at $79,786,000 after buying an additional 439,437 shares during the last quarter. First Light Asset Management LLC bought a new stake in Takeda Pharmaceutical in the second quarter valued at $431,000. Finally, Veriti Management LLC lifted its stake in Takeda Pharmaceutical by 3.6% in the third quarter. Veriti Management LLC now owns 21,842 shares of the company’s stock valued at $358,000 after buying an additional 768 shares during the last quarter. Institutional investors own 2.90% of the company’s stock.

A number of research firms have issued reports on TAK. Morgan Stanley cut Takeda Pharmaceutical from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, October 6th. Jefferies Financial Group upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Friday, October 29th. The Goldman Sachs Group cut shares of Takeda Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, Zacks Investment Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Hold” and an average target price of $19.00.

NYSE:TAK opened at $14.75 on Friday. The business’s 50-day moving average price is $13.85 and its 200 day moving average price is $15.34. The firm has a market cap of $46.68 billion, a P/E ratio of 9.34 and a beta of 0.94. Takeda Pharmaceutical Company Limited has a 52-week low of $13.17 and a 52-week high of $19.97. The company has a quick ratio of 0.87, a current ratio of 1.28 and a debt-to-equity ratio of 0.75.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, October 28th. The company reported $0.45 earnings per share (EPS) for the quarter. The firm had revenue of $7.67 billion for the quarter. Takeda Pharmaceutical had a return on equity of 12.66% and a net margin of 15.78%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.29 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Co, Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products.

Read More: Is the Dow Jones Industrial Average (DJIA) still relevant?

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.